Chinese Academy of Medical Sciences, Fuwai Hospital
Jun CAI
STEP-Pre is to investigate the benefits of using anti-hypertensive drugs in the population with a blood pressure of 130-139/80-89 mmHg and evaluate the health economics. STEP-Pre is a multi-center randomized clinical trial. The cohort will be randomized into the treatment group or control group with a 1:1 ratio. The treatment group will take anti-hypertensive medicine to control blood pressure under 130/80 mmHg. Both groups will take health care education. STEP-Pre will last 4 years.
Cardiovascular Diseases
RASI and/or a single pill combination based RASI
Not Applicable
Study Type : | Interventional |
Estimated Enrollment : | 20000 participants |
Masking : | Single |
Primary Purpose : | Prevention |
Official Title : | Study of Early Pharmaceutical Intervention for Cardiovascular Disease Prevention in Stage 1 Hypertension |
Actual Study Start Date : | January 1, 2023 |
Estimated Primary Completion Date : | December 31, 2026 |
Estimated Study Completion Date : | December 31, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment Antihypertensive drugs will be provided to the participants in the arm, including RASI and/or a single pill combination based on RASI. If the blood pressure of a participant elevates to above 140/90 mmHg, antihypertensive therapy will be provided. |
|
No Intervention: Control If the blood pressure of a participant elevates to above 140/90 mmHg, antihypertensive therapy will be provided. |
Ages Eligible for Study: | 35 Years to 64 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.